Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
LENUREX-K® TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): LENUREX-K ® TABLETS COMPOSITION: Each tablet contains: Cyclopenthiazide 0,25 mg Potassium Chloride 600 mg The Potassium Chloride is incorporated into a specially formulated slow-release core. PHARMACOLOGICAL CLASSIFICATION: A 18.1 Diuretics PHARMACOLOGICAL ACTION: Lenurex-K is a diuretic which reduces the reabsorption of electrolytes from the renal tubules, thereby increasing the excretion of sodium, potassium and chloride ions, and consequently of water. It also slightly increases bicarbonate excretion without appreciable alteration of the acid-base balance or the pH of the urine, it has a lowering effect on the blood pressure and enhances the action of other hypotensive agents. Cyclopenthiazide is absorbed from the gastro-intestinal tract, distributed throughout the extracellular space and diffuses across the placenta. Diuresis occurs in about two hours, reaches a maximum in about four hours, and lasts for about twelve hours. Tolerance does not develop and therapeutic efficacy is maintained when it is administered over long periods, but patients may not respond if their glomerular filtration-rate is markedly reduced. This medicine contains potassium chloride. It has not been proven that this dosage will necessarily prevent a significant potassium loss or correct an existing deficiency of potassium. INDICATIONS: Oedema due to sodium and water retention. In patients with diabetes insipidus, cyclopenthiazide decreased urinary volume and may therefore be of value in the management of the disease. Essential hypertension: preferably in combination with other antihypertensive agents. CONTRA-INDICATIONS: Patients with an established hypersensitivity towards the drug. Severe renal and/or hepatic insufficiency. DOSAGE AN Read the complete document